Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Goldenberries taste like a cross between pineapple and mango, pack the nutritional punch of a superfood, and are increasingly ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

CRISPR technology, a revolutionary tool in genetic engineering, has empowered Lambert's iGEM team to tackle a significant health issue: Lyme disease, which affects nearly half a million Americans ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...

Teens at a Georgia high school may have come up with a better way to detect and treat Lyme disease. They took their idea to ...

The outlook for dementia care is changing fast. UC experts explain what that means for patients and families, and what it ...

Genetic engineering is moving from the lab bench into clinics, farms, and even family planning decisions, promising to change ...